Treating subclinical leaflet thrombosis after TAVR has been an ongoing challenge for structural heart clinicians, but recent research has gone a long way toward improving our understanding of this important topic. 

In-hospital mortality was especially high among TAVR patients presenting with hypertrophic cardiomyopathy, according to a new analysis.

Brijeshwar Maini, MD, explains his decision to leave clinical practice to become a full-time cardiac device business owner. It is a path several prominent cardiologists have made.

Anita W. Asgar, MD, director, transcatheter valve therapy research at Montréal Heart Institute, discusses advances and new technology for mitral and tricuspid valves at the 2022 Transcatheter Valve Therapies (TVT) meeting. 

However, the study’s authors did find associations between suboptimal TAVR procedures and adverse outcomes.

Cardiologist Peter Fail, MD, discusses the idea of using shunts to form a passage that enables the left atrium to decompress at rest and during physical activity. The goal is to lower left atrial pressure in heart failure patients.

The new analysis focused on transcatheter edge-to-edge repair and left atrial appendage occlusion procedures.

The study, published in the American Journal of Cardiology, included data from more than 900 TAVR patients. Overall morality was 22.7% among patients with AFib and 14.4% among patients without AFib.